Inhibitor of apoptosis protein‑like protein‑2: A novel growth accelerator for breast cancer cells

凋亡蛋白样蛋白2抑制剂:乳腺癌细胞的新型生长加速剂

阅读:5
作者:Lin Zhu, Weihua Zhou, Xidi Zhu, Siqi Xiang, Siyuan Wang, Yingxia Peng, Bangyun Lu, Peizhi Tang, Qian Chen, Mengjuan Wu, Xia Peng, Ziyu Chen, Ziyi Sun, Kunliang Yang, Mingjun Xiang, Dandan Yu

Abstract

Although the inhibitor of apoptosis protein‑like protein‑2 (ILP‑2) has been shown as a serological biomarker for breast cancer, its effect on breast cancer cell growth remains elusive. The present study aimed to determine the role of ILP‑2 in breast cancer cell growth. We used immunohistochemistry to analyze ILP‑2 expression in 59 tissue paraffin‑embedded blocks, which included 35 breast cancer tissues and 24 galactophore hyperplasia tissues. Western blot analysis was used to detect protein expression levels of ILP‑2 in breast cancer cell lines such as HCC‑1937, MX‑1 and MCF‑7 as well as breast gland cell line MCF 10A. ILP‑2 was silenced by siRNA in HCC‑1937, MX‑1 and MCF‑7 cell lines. MTT assays, scratch assays and AO‑EB double staining analysis were conducted to evidence the role of ILP‑2 on breast cancer cell growth. Results from this study showed increased ILP‑2 expression in breast cancer tissues and breast cancer cell lines such as HCC‑1937, MX‑1 and MCF‑7. Cell viability or rate of cell migration of HCC‑1937, MX‑1 and MCF‑7 cell lines was significantly inhibited when ILP‑2 was knocked down by siRNA. The apoptosis rate of HCC‑1937, MX‑1 and MCF‑7 cell lines was increased when compared with that of the control group. Thus, ILP‑2 plays an active role in the growth of breast cancer cells.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。